aTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B. The Company is developing Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component (RMICs). The Company is investigating Resolaris in patients with LGMD2B. The Company is conducting approximately three open label trials in patients with early onset FSHD, in adult patients with FSHD or LGMD2B and a long-term extension study in adult patients with FSHD. The Company has not generated any revenues.
https://www.atyrpharma.com/J2T SERVICES LTD provides its services only to Professional Clients and Eligible Counterparties
© 2026 J2T Services Ltd
J2T Services Ltd diotorisasi dan diatur oleh Komisi Sekuritas dan Bursa Siprus sesuai dengan lisensi No.281/15 yang dikeluarkan pada 25/09/2015. Trademark "Just2Trade" dimiliki oleh J2T SERVICES LTD.
Nomor Registrasi: HE 341520
Alamat: J2T Services Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Penafian: Semua promosi, materi, dan informasi situs web ini mungkin memiliki ketentuan yang berlaku. Silakan hubungi Perusahaan untuk keterangan lebih lanjut
Trading di pasar keuangan mengandung risiko. Nilai investasi bisa naik atau turun, dan investor bisa kehilangan semua modal investasinya. Dalam hal produk dengan leverage, nilai kerugian mungkin saja lebih besar dibandingkan modal awal investasi. Informasi terperinci tentang risiko terkait dengan trading di pasar keuangan dapat ditemukan di Syarat dan Ketentuan Umum untuk Penyediaan Layanan Investasi.
Tel: +357 25 055 966
E-mail: 24_support@j2t.com